Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ARJIL Pharmaceuticals is a clinical-stage biopharmaceutical company founded in Taiwan in 2014. It develops innovative botanical-based medicines and small molecules targeting age-related conditions and immune/inflammatory disorders. Its lead program AR‑100 has reached Phase I/II trials for atopic dermatitis; other pipeline assets remain preclinical or earlier.[6][3] The company has raised over $8 million USD in funding as of early 2024.[6] No commercialized products yet.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ARJIL Pharmaceuticals.